Laboratorios Kener raises investment to MXN 10.54 billion to expand pharmaceutical production in Mexico

Laboratorios Kener announced an expansion of its pharmaceutical infrastructure investment plan in Mexico, with new projects totaling MXN 5.36 billion. Added to the MXN 5.18 billion previously announced last July, the company’s total investment reaches MXN 10.54 billion, aimed at strengthening national production, biotechnology and specialized medicines.

Federico Prince, CEO of Laboratorios Kener, said the company seeks to reinforce the country’s pharmaceutical sovereignty through new production capabilities and strategic alliances focused on innovation and advanced manufacturing.

“Today, we reaffirm our commitment to your government and to the Mexican State, with the health of Mexican women and men as a priority.”

Expansion of Toluca plant drives injectable production

Among the announced projects is the expansion of Kener’s production plant in Toluca, State of Mexico, with an additional investment of MXN 550 million for the manufacturing of high-volume injectable products.

Prince explained that the equipment has already been acquired and is currently in the manufacturing process before being installed in Mexico.

“The machinery has already been acquired and is being manufactured, and it will soon be delivered here in Mexico.”

Kener to invest in biotechnology and plasma-derived products plant

The plan also includes the construction of a plasma-derived products plant through a strategic co-investment with the Government of Mexico for MXN 1.35 billion, as well as the development of a biotechnology plant with an investment of MXN 3.46 billion in alliance with a multinational company.

According to the executive, this infrastructure will allow the company to position itself within larger-scale biotechnology innovation processes.

“A biotechnology plant with an investment of MXN 3.46 billion, in alliance with a multinational company, will place us at the forefront of innovation in biotechnology.”

Prince stated that the investments will contribute to the creation of more than 3,500 direct and indirect jobs, while also expanding national pharmaceutical manufacturing capabilities.

“These investments undoubtedly strengthen the country’s pharmaceutical sovereignty and will generate more than 3,500 direct and indirect jobs.”